Analyzing Tvardi Therapeutics (NASDAQ:TVRD) & Scienture (NASDAQ:SCNX)

Scienture (NASDAQ:SCNX) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Scienture and Tvardi Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	1	0	2.00
Tvardi Therapeutics	1	1	6	1	2.78

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 352.49%. Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 922.73%. Given Tvardi Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Scienture.

Volatility and Risk

Scienture has a beta of 3.25, suggesting that its share price is 225% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.

Valuation and Earnings

This table compares Scienture and Tvardi Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	31.65	-$41.51 million	($2.10)	-0.16
Tvardi Therapeutics	$7.14 million	3.29	-$18.21 million	($2.79)	-0.63

Tvardi Therapeutics has higher revenue and earnings than Scienture. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Scienture and Tvardi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.